Pfizer Inc. (NYSE:PFE) Shares Acquired by Hennessy Advisors Inc.

Hennessy Advisors Inc. increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.9% in the first quarter, HoldingsChannel.com reports. The firm owned 183,800 shares of the biopharmaceutical company’s stock after buying an additional 5,200 shares during the period. Hennessy Advisors Inc.’s holdings in Pfizer were worth $5,100,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. VisionPoint Advisory Group LLC increased its stake in Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 1,047 shares during the period. GoalVest Advisory LLC raised its stake in shares of Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 811 shares in the last quarter. Creekmur Asset Management LLC purchased a new position in shares of Pfizer during the fourth quarter worth approximately $32,000. Tennessee Valley Asset Management Partners purchased a new stake in Pfizer in the 4th quarter valued at $36,000. Finally, DiNuzzo Private Wealth Inc. acquired a new position in Pfizer in the fourth quarter valued at $37,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of research reports. BMO Capital Markets reissued an “outperform” rating and set a $36.00 price target (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Morgan Stanley raised their price objective on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, May 2nd. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Wednesday. Finally, Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Ten research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $35.86.

Pfizer Price Performance

Pfizer stock traded up $0.38 during mid-day trading on Thursday, hitting $27.80. 27,944,899 shares of the company were exchanged, compared to its average volume of 40,970,031. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $37.80. The company has a market capitalization of $157.53 billion, a P/E ratio of -458.26, a PEG ratio of 1.10 and a beta of 0.70. The business’s 50 day simple moving average is $27.81 and its two-hundred day simple moving average is $27.69. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78.

Pfizer (NYSE:PFE) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.26. The firm had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The firm’s revenue for the quarter was down 19.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.23 EPS. Analysts forecast that Pfizer Inc. will post 2.38 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be paid a $0.42 dividend. The ex-dividend date of this dividend is Friday, July 26th. This represents a $1.68 annualized dividend and a yield of 6.04%. Pfizer’s payout ratio is currently -2,799.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.